“Doctors have basically been taught and raised and are functioning in a system where addiction is always someone else’s job,” said Priya Mammen, an emergency physician and public health advocate from South Philadelphia. “The regulations treat these medications as qualitatively different from any other medication we prescribe. It gives off Read more…
Inmates are being denied treatment, and it’s creating an epidemic. On May 15, 2017, after serving 37 years, David Maldonado was released from prison. He had been sentenced to life for a murder he committed when he was 16. But for Maldonado, getting out was about more than freedom; his Read more…
Hepatitis C Provider Live Webinar Training February 14, 2019 (4:30pm – 5:30pm) Alyson Harty, RN, BSN Clinical Nurse Manager Mount Sinani Institute for Liver Medicine One hour of CME/CNE/CEU credit per webinar – Free for MD, DO, NP, PA, RN clinical providers This is a great opportunity to learn about Read more…
Hepatitis C Clinical Provider Live Webinar Training January 24, 2019 (4:30pm – 5:30pm) Hosted by Dr. Jeffrey Weiss, PhD Associate Professor, Department of Medicine & Director, REACH Program Division of General Internal Medicine, Icahn School of Medicine One hour of CME/CNE/CEU credit per webinar – Free For MD, DO, NP, Read more…
A new Medical Assistance Bulletin from the The Pennsylvania Department of Human Services, effective Dec. 17, issues updated handbook pages that include the requirements for prior authorization and the type of information needed to evaluate the medical necessity of prescriptions for Hepatitis C Agents submitted for prior authorization. This bulletin Read more…
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa®(sofosbuvir 400mg/velpatasvir 100mg) and Harvoni®(ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will launch Read more…
“Taking Steps to Good Care & Long Term Health” is a free community forum on Thursday, November 8th, organized by the National AIDS Treatment Advocacy Project and co-sponsored by HepCAP. While HepCAP meetings are on hold, this morning forum is a great way to get updated on the latest information Read more…
Coordinated care has the potential to improve access to treatment for individuals with hepatitis C who are naive to direct-acting antivirals; however, having Medicaid could hamper access, according to a recent study published in PLoS ONE. In this study, an integrated treatment team at the Vanderbilt University Medical Center in Tennessee provided care Read more…
Access Minutes Here The Committee reviewed the Hepatitis C Agents class and unaminously approved adding Mavyret to the PDL at preferred status, moving Pegasys, Pegintron, Sovaldi, Technivie, Viekira Pak and Viekira XR to non-preferred status, and adding Vosevi to the PDL at non-preferred status. The Committee recognized the changing landscape Read more…
Help-4-Hep can help with client communications, support, referrals and linkage to care. Is your organization challenged by one-on-one conversations with clients? Do you spend too much time searching for financial resources and linkage-to-care for your clients? And answering the same old questions? Are client callers distracting you from the responsibilities Read more…